Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study

医学 儿科 呼吸道感染 呼吸系统 人口 泊松回归 公共卫生 毛细支气管炎 帕利珠单抗 急诊医学 环境卫生 内科学 护理部
作者
Sonia Ares‐Gómez,Narmeen Mallah,María-Isolina Santiago-Pérez,Jacobo Pardo‐Seco,Olaia Pérez‐Martínez,María‐Teresa Otero‐Barrós,Nuria Súarez‐Gaiche,Rolf Kramer,Jing Jin,Leticia Platero-Alonso,Rosa‐María Alvárez‐Gil,Olga‐María Ces‐Ozores,Victoria Nartallo‐Penas,Susana Mirás‐Carballal,Marta Piñeiro-Sotelo,Alberto Malvar‐Pintos,Juan‐Manuel González‐Pérez,Carmen Rodríguez‐Tenreiro,Irene Rivero‐Calle,Antonio Salas
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (8): 817-828 被引量:232
标识
DOI:10.1016/s1473-3099(24)00215-9
摘要

Background Galicia (Spain) was one of the first regions worldwide to incorporate nirsevimab for universal respiratory syncytial virus (RSV) prophylaxis in infants into its immunisation programme. The NIRSE-GAL longitudinal population-based study aimed to assess nirsevimab effectiveness in preventing hospitalisations (ie, admittance to hospital). Methods The 2023–24 immunisation campaign with nirsevimab in Galicia began on Sept 25, 2023, and concluded on March 31, 2024. The campaign targeted three groups: infants born during the campaign (seasonal group), infants younger than 6 months at the start of the campaign (catch-up group), and infants aged 6–24 months with high-risk factors at the start of the campaign (high-risk group). Infants in the seasonal group were offered immunisation on the first day of life before discharge from hospital. Infants in the catch-up and high-risk groups received electronic appointments to attend a public hospital or health-care centre for nirsevimab administration. For this interim analysis, we used data collected from Sept 25 to Dec 31, 2023, from children born up to Dec 15, 2023. Data were retrieved from public health registries. Nirsevimab effectiveness in preventing RSV-associated lower respiratory tract infection (LRTI) hospitalisations; severe RSV-related LRTI requiring intensive care unit admission, mechanical ventilation, or oxygen support; all-cause LRTI hospitalisations; and all-cause hospitalisations was estimated using adjusted Poisson regression models. Data from five past RSV seasons (2016–17, 2017–18, 2018–19, 2019–20, and 2022–23), excluding the COVID-19 pandemic period, were used to estimate the number of RSV-related LRTI hospitalisations averted along with its IQR. The number needed to immunise to avoid one case in the 2023–24 season was then estimated from the averted cases. Nirsevimab safety was routinely monitored. The NIRSE-GAL study protocol was registered on ClinicalTrials.gov (NCT06180993), and follow-up of participants is ongoing. Findings 9408 (91·7%) of 10 259 eligible infants in the seasonal and catch-up groups received nirsevimab, including 6220 (89·9%) of 6919 in the seasonal group and 3188 (95·4%) of 3340 in the catch-up group. 360 in the high-risk group were offered nirsevimab, 348 (97%) of whom received it. Only infants in the seasonal and catch-up groups were included in analyses to estimate nirsevimab effectiveness and impact because there were too few events in the high-risk group. In the catch-up and seasonal groups combined, 30 (0·3%) of 9408 infants who received nirsevimab and 16 (1·9%) of 851 who did not receive nirsevimab were hospitalised for RSV-related LRTI, corresponding to an effectiveness of 82·0% (95% CI 65·6–90·2). Effectiveness was 86·9% (69·1–94·2) against severe RSV-related LRTI requiring oxygen support, 69·2% (55·9–78·0) against all-cause LRTI hospitalisations, and 66·2% (56·0–73·7) against all-cause hospitalisations. Nirsevimab effectiveness against other endpoints of severe RSV-related LRTI could not be estimated because of too few events. RSV-related LRTI hospitalisations were reduced by 89·8% (IQR 87·5–90·3), and the number needed to immunise to avoid one RSV-related LRTI hospitalisation was 25 (IQR 24–32). No severe adverse events related to nirsevimab were registered. Interpretation Nirsevimab substantially reduced infant hospitalisations for RSV-associated LRTI, severe RSV-associated LRTI requiring oxygen, and all-cause LRTI when given in real-world conditions. These findings offer policy makers and health authorities robust, real-world, population-based evidence to guide the development of strategies for RSV prevention. Funding Sanofi and AstraZeneca. Translation For the Spanish translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
迷人的中药材完成签到 ,获得积分10
刚刚
楚留香发布了新的文献求助10
刚刚
彭于晏的应助被111采纳,获得30
1秒前
1秒前
CengcEng发布了新的文献求助10
1秒前
2秒前
隐形曼青的应助被郭欣茹采纳,获得10
2秒前
2秒前
临肃01发布了新的文献求助10
2秒前
小寻一看就是老实人给小寻一看就是老实人的求助进行了留言
2秒前
Hot发布了新的文献求助10
2秒前
NexusExplorer的应助被鹰隼游采纳,获得10
2秒前
winny_发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
坚定海莲发布了新的文献求助80
3秒前
旗亭画壁完成签到,获得积分10
3秒前
sea完成签到,获得积分10
3秒前
ding的应助被崔正采纳,获得10
3秒前
专业论文的应助被裸奔的馒头采纳,获得10
4秒前
4秒前
情怀的应助被Ccc采纳,获得10
4秒前
酷波er的应助被小带采纳,获得10
4秒前
4秒前
斯文败类的应助被Code_king采纳,获得10
5秒前
CipherSage的应助被Code_king采纳,获得10
5秒前
英俊的铭的应助被Code_king采纳,获得10
5秒前
所所的应助被Cookies采纳,获得10
5秒前
搜集达人的应助被Code_king采纳,获得10
5秒前
柳成荫完成签到,获得积分20
5秒前
隐形曼青的应助被Code_king采纳,获得10
5秒前
研友_VZG7GZ的应助被Code_king采纳,获得10
5秒前
深情安青的应助被Code_king采纳,获得10
5秒前
5秒前
上官若男的应助被Code_king采纳,获得10
5秒前
华仔的应助被Code_king采纳,获得10
5秒前
爆米花的应助被Code_king采纳,获得10
5秒前
吴晨曦发布了新的文献求助10
6秒前
chenhaoran发布了新的文献求助10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176287
求助须知:如何正确求助?哪些是违规求助? 9567719
关于积分的说明 21794359
捐赠科研通 7771008
什么是DOI,文献DOI怎么找? 3431998
关于科研通互助平台的介绍 2556315
邀请新用户注册赠送积分活动 2477650